Liver cirrhosis
Conditions
Interventions
1) Angiotensin II receptor blocker 2) Branched-chain amino acids Use normal dose
1) Angiotensin II receptor blocker Use normal dose
1) Branched-chain amino acids Use normal dose
No medicatio
Sponsors
The third department of internal medicine, Nara Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients over 20 years old 2) Patients obtained written informed consent 3) Life expectancy of at least 12 weeks 4) Patients with an ECOG Performance Status (PS) score of 0 or 1 5) Patinets with Child-Pugh class A, B cirrhosis 6) Adequate organ function a.Hb>= 8.0g/dL b.Neutrophil>=1500 /mm3 c.PLT>= 50000 /mm3 d.T-Bil< 3.0 mg/dL e.AST and ALT<= within 6 times of normal limit f.Cre<= within 1.5 times of normal limit
Exclusion criteria
Exclusion criteria: 1) Patients with malignant tumor 2) Patients with severe heart disease 3) Patients with severe and active infectious disease except viral hepatitis 4) Patients with HIV 5) Patients with severe renal dysfunction 6) Patienst with intracranial tumor 7) Patients with on going refractory hepatic coma 8) Patients with refractory ascites and pleural effusion 9) Patients with crutial digestive bleedings within 4 weeks 10) Ptients with intravascular thrombosis within 6 months except portal thrombosis 11) Patients with the following issues a. Systemic chemotherapy against HCC b. Partial hepatectomy or local treatment against HCC within 4 weeks c. Being treated with anticoagulant drugs d. Being treated with invasive surgical therapy within 4 weeks e. Having been treated with organ transplantation f. Being treated with bone marrow transplantation within 4 weeks 12) Patients with oral intake difficulty 13) Patients with severe digestive diseases 14) Patients taking a tablet which would affect this clinical study 15) Patients without normal absorbing function 16) Patients having been resistered in other clinical study within 4 weeks 17) Pregnant woman, lactating woman, or a woman suspected of pregnancy 18) Patients with severe allergic reaction 19) Patients with drug abuse or psycological disorders 20) Patients taking aliskiren hemifumarate 21) Patients concluded to be inappropriate to participate in this study by their physitians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Periods between the date of primary resistration and the date of newly occurred varices recognition in digestive organs | — |
Secondary
| Measure | Time frame |
|---|---|
| Periods between the date of primary resistration and the date of varices rupture (or very similar situation to rupture) in digestive organs | — |
Countries
Japan
Contacts
Public ContactKEI MORIYA
Nara Medical University The third department of internal medicine
Outcome results
None listed